GenCab: Molecular profiling of tumour pathways determining Cabazitaxel sensitivity and resistance

Trial Profile

GenCab: Molecular profiling of tumour pathways determining Cabazitaxel sensitivity and resistance

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Cabazitaxel (Primary)
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Acronyms GENCAB
  • Most Recent Events

    • 07 Sep 2015 Planned End Date changed from 1 Oct 2015 to 1 Aug 2015, as reported by United Kingdom Clinical Research Network record.
    • 07 Sep 2015 Status changed from recruiting to active, no longer recruiting, as reported by United Kingdom Clinical Research Network record.
    • 04 Dec 2014 Accrual to date is 20% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top